All Resources
Our resource hub to discover reports, policy papers and other forms of informative content
Increasing Access to Innovative Medicines
The impact of the COVID-19 pandemic has shifted the health landscape in Canada. While the federal government has demonstrated its ability to react to an unprecedented health crisis, doing so has also sharpened the focus on domestic capacity and innovation in the life sciences sector.
Throughout the pandemic, we could not be prouder of our members’ collaborative efforts worldwide. From the onset, they worked toward agreements with nations and competitors to increase manufacturing capacity and minimize pharmaceutical supply chain disruption. IMC members demonstrated the industry’s value to the world, as the critical importance of reliable access to medicines was brought into focus.
Alberta Budget Submission 2023
Innovative Medicines Canada (IMC) is the national association representing Canada’s innovative pharmaceutical industry. The association advocates for policies that promote the discovery, development and delivery of innovative medicines and vaccines to improve the lives of all Canadians. In addition, it supports the commitment of its members as valued partners in the Canadian healthcare system.
The association represents 50 companies, which invest nearly $1.4 billion annually in research and development. In this way, it nurtures a high value-added knowledge economy while contributing $8 billion to the national economy.
2022 Federal Pre-Budget Consultation
Our industry calls on the federal government to implement measures under the Biomanufacturing and Life Sciences Strategy to build a more vibrant life sciences sector and enhance patients’ access to innovative medicines.
Pre-Budget Consultations in advance of the upcoming 2021 Federal Budget
IMC recommends striking a balance among affordability and access to innovative medicines and vaccines, allocating more funding and research incentives over five years, and developing a national life sciences strategy.
